MedPath
FDA Approval

DOJOLVI

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
June 19, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Triheptanoin(0.96 g in 1 mL)

Manufacturing Establishments7

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

962892019

Haupt Pharma Wolfratshausen GmbH

Ultragenyx Pharmaceutical Inc.

314715889

GBA Pharma GMbH

Ultragenyx Pharmaceutical Inc.

342374604

Labor LS SE & CO. KG.

Ultragenyx Pharmaceutical Inc.

314929072

Integrated Commercialization Solutions, LLC

Ultragenyx Pharmaceutical Inc.

832820588

IOI Oleo GmbH & Co. KG

Ultragenyx Pharmaceutical Inc.

342589974

AndersonBrecon Inc. (PCI Pharma Services) USA

Ultragenyx Pharmaceutical Inc.

053217022

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DOJOLVI

Product Details

NDC Product Code
69794-050
Application Number
NDA213687
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
June 19, 2023
Code: 2P6O7CFW5KClass: ACTIBQuantity: 0.96 g in 1 mL
© Copyright 2025. All Rights Reserved by MedPath